FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib)

Sep 25, 2025 11:26AM ● By U.S. Food & Drug Administration News Release

Agency determines special restrictions are no longer necessary to ensure the benefits of thyroid cancer treatment with Caprelsa outweigh its risks.